Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

First Posted Date
2006-04-03
Last Posted Date
2016-02-03
Lead Sponsor
AIDS Malignancy Consortium
Registration Number
NCT00310128

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

First Posted Date
2006-03-13
Last Posted Date
2021-03-30
Lead Sponsor
Children's Oncology Group
Target Recruit Count
287
Registration Number
NCT00302003
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

First Posted Date
2006-03-06
Last Posted Date
2021-09-21
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT00299182
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2006-02-24
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
53
Registration Number
NCT00295841
Locations
🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

First Posted Date
2006-02-13
Last Posted Date
2020-09-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
55
Registration Number
NCT00290433
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

First Posted Date
2006-02-13
Last Posted Date
2020-06-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
67
Registration Number
NCT00290498
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

First Posted Date
2006-01-25
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
200
Registration Number
NCT00281879
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2006-01-13
Last Posted Date
2014-04-17
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registration Number
NCT00276601
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

🇺🇸

Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 4 locations

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Chronic Lymphocytic Leukemia
First Posted Date
2006-01-13
Last Posted Date
2016-09-26
Lead Sponsor
German CLL Study Group
Target Recruit Count
30
Registration Number
NCT00276809
Locations
🇩🇪

Medizinische Hochschule Hannover, Hannover, Germany

🇩🇪

Universitatsklinikum Heidelberg, Heidelberg, Germany

🇩🇪

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Phase 3
Terminated
Conditions
Lymphoma
First Posted Date
2006-01-11
Last Posted Date
2013-07-10
Lead Sponsor
Children's Cancer and Leukaemia Group
Target Recruit Count
600
Registration Number
NCT00275106
Locations
🇬🇧

Addenbrooke's Hospital, Cambridge, England, United Kingdom

🇬🇧

Royal Manchester Children's Hospital, Manchester, England, United Kingdom

🇩🇪

Kinderklinik, Giessen, Germany

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy